This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)

This study has been completed.
Information provided by (Responsible Party):
Eisai Inc. Identifier:
First received: May 15, 2012
Last updated: December 29, 2016
Last verified: December 2016
Subjects will be adults aged 50 to 85 years who have subjective memory complaints and mild cognitive impairment or mild dementia due to Alzheimer's disease (AD). Subjects taking thyroxine or thyroid supplements and subjects receiving an acetylcholinesterase inhibitor (AChEI) and/or memantine for AD must be on a stable dose for at least 12 weeks prior to Screening and remain on their stable dose throughout the trial. Subjects will receive placebo or a single oral dose of E2609. Safety assessments will be conducted. Additionally, the pharmacokinetics of E2609 and drug effects will be evaluated using cerebrospinal fluid biomarkers and cognitive and psychological measures.

Condition Intervention Phase
Alzheimer's Disease Drug: E2609 Drug: Placebo for E2609 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease

Resource links provided by NLM:

Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • Percent change from baseline in cerebrospinal fluid amyloid-beta levels [ Time Frame: baseline to 36 hours post-dose ]

Secondary Outcome Measures:
  • Incidence of adverse events [ Time Frame: 8 days ]

Enrollment: 65
Study Start Date: July 2012
Study Completion Date: October 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: E2609 Drug: E2609

E2609 capsules: 5 mg, 25 mg, 50 mg, and 200 mg

E2609 doses: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, and 400 mg

According to the randomized study design, participants who are assigned to receive E2609 will each receive a single assigned dose consisting of two capsules of E2609 or in some cases one capsule of E2609 and one of placebo

Placebo Comparator: Placebo for E2609 Drug: Placebo for E2609

Placebo capsules

According to the randomized study design, participants who are assigned to receive placebo will each receive a single dose consisting of two capsules of placebo


Ages Eligible for Study:   50 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Meets the current cognitive classification of MCI or mild dementia due to AD pathology (all subjects having a "positive" biomarker for amyloid β) as defined by the National Institute on Aging - Alzheimer's Association (NIA-AA) research criteria
  • Aged 50 to 85 years, inclusive at time of consent

Exclusion criteria:

  • Currently has any neurological condition other than AD (Alzheimer's disease)-related that could be contributing to the subject's cognitive impairment
  • Significant pathological findings on brain MRI at Screening, including but not limited to multiple microhemorrhages
  • Any psychiatric diagnosis or symptoms, e.g., hallucinations, major depression,anxiety or delusions that in the Investigator's opinion could interfere with assessment of cognition or confound the diagnosis of MCI or mild dementia due to AD in the subject.
  • A lifetime history of cerebrovascular events or non-vasovagal related loss of consciousness within the last 10 years
  • Any other abnormality of the ECG at Screening and/or Baseline (including QRS > 110 ms, abnormal electrical axis, PR interval > 220 ms and conduction abnormalities) considered clinically significant by the investigator
  • History of cardiac arrhythmias, ischemic heart disease or cerebrovascular disease
  • Lower spinal malformation on physical or lumbar spine radiography, local spinal infection, or other abnormality, including but not limited to obesity, that would prevent LP or insertion of an indwelling catheter for CSF sampling
  • Any history of seizure disorder, symptomatic seizures (not including a history of simple febrile seizures in childhood) or any past or present medical condition which, in the opinion of the investigator has the potential to reduce seizure threshold (e.g., history of head trauma or concussion, previous alcohol abuse, substance abuse).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01600859

United States, California
Glendale, California, United States
United States, Maryland
Baltimore, Maryland, United States
Sponsors and Collaborators
Eisai Inc.
Principal Investigator: Hakop Gevorkyan California Clinical Trials Medical Group Inc.
Principal Investigator: Olukemi Olugemo, MD PAREXEL International - EPCU Baltimore
  More Information

Responsible Party: Eisai Inc. Identifier: NCT01600859     History of Changes
Other Study ID Numbers: E2609-A001-101
Study First Received: May 15, 2012
Last Updated: December 29, 2016

Additional relevant MeSH terms:
Alzheimer Disease
Cognition Disorders
Mild Cognitive Impairment
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders processed this record on September 21, 2017